This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the disease-free survival and overall survival effects of interferon alpha as adjuvant treatment for people with high-risk cutaneous melanoma. Adverse events and quality of life, even if they represent a crucial issue in interferon alpha treatment, will not be addressed in the present study, as virtually all trials have compared interferon treatment with observation (i.e. no treatment).